News

Jerusalem, Israel, March 6, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)announced today that it will continue to sell its generic version of OxyContin® tablets at least through the end of 2007. In October 2006, Teva settled a patent dispute with the Purdue Frederick Company and certain of its affiliates pertaining to Teva's generic version of Purdue's OxyContin® (oxycodone HCl extended-release) tablets. The settlement provided a full release of Teva and its distributors, purchasers and patients and requires Teva to cease sales of the product upon the occurrence of certain continge Read More »

Jerusalem, May 11, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Bank of America Merrill Lynch Health Care Conference with Shlomo Yanai, President & Chief Executive Officer, Teva Pharmaceutical Industries Ltd., presenting on Thursday, May 13, 2010 in New York.What: Teva Presentation at the Bank of America Merrill Lynch Annual Health Care ConferenceWho: Shlomo Yanai, President & Chief Executive Officer, Teva Pharmaceutical Industries Ltd.When: Thursday, May 13, 2010 at 10:40 AM (ET)Where: https://www.veracast.com/webcasts/bas/healthcare2 Read More »

Jerusalem, Israel, July 16, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid. The Court also denied Wyeth and Nycomed's request for FDA to reset the date of Teva's final approval to January 2011, based on the fact that Teva has patent defenses remaining at the District Court, including patent misuse. Accordingly, Teva is not prohibited from making further sales prior to January 2011, the date when the pediat Read More »

Jerusalem, July 23, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) commented today on the U.S. Food and Drug Administration's response to a citizen petition questioning the approval criteria for a generic Lovenox® (enoxaparin sodium) injection and its subsequent approval of another generic filer's Abbreviated New Drug Application (ANDA).After reviewing the FDA's response to the citizen petition, which outlines 5 criteria to demonstrate "sameness", Teva believes that it has demonstrated to the FDA that its version of generic Lovenox meets their criteria and that Teva's pend Read More »